Результати пошуку - Deborah A. Thomas

Уточнити результати
  1. 1
    Monoclonal Antibody-Based Therapies: A New Dawn in the Treatment of Acute Lymphoblastic Leukemia

    Monoclonal Antibody-Based Therapies: A New Dawn in the Treatment of Acute Lymphoblastic Leukemia за авторством Hagop M. Kantarjian, Deborah A. Thomas, Alan S. Wayne, Susan O’Brien

    Опубліковано 2012
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  2. 2
    Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia

    Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia за авторством Michael Rytting, Lisa Triche, Deborah A. Thomas, Susan O’Brien, Hagop M. Kantarjian

    Опубліковано 2013
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  3. 3
    Philadelphia-Positive Acute Lymphoblastic Leukemia: Current Treatment Options

    Philadelphia-Positive Acute Lymphoblastic Leukemia: Current Treatment Options за авторством Theresa Liu-Dumlao, Hagop M. Kantarjian, Deborah A. Thomas, Susan O’Brien, Farhad Ravandi

    Опубліковано 2012
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  4. 4
    Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia

    Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia за авторством Susan O’Brien, Deborah A. Thomas, Farhad Ravandi, Stefan Faderl, Sherry Pierce, Hagop M. Kantarjian

    Опубліковано 2008
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  5. 5
    Aberrant Underexpression of CD81 in Precursor B-Cell Acute Lymphoblastic Leukemia

    Aberrant Underexpression of CD81 in Precursor B-Cell Acute Lymphoblastic Leukemia за авторством Tariq Muzzafar, L. Jeffrey Medeiros, Sa A. Wang, Archana Brahmandam, Deborah A. Thomas, Jeffrey L. Jorgensen

    Опубліковано 2009
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  6. 6
    Use of arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) in the treatment of patients with acute promyelocytic leukemia

    Use of arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) in the treatment of patients with acute promyelocytic leukemia за авторством Guillermo Lazo, Hagop M. Kantarjian, Elihu H. Estey, Deborah A. Thomas, Susan O’Brien, Jorge E. Cortés

    Опубліковано 2003
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  7. 7
    Comparison of thalidomide and lenalidomide as therapy for myelofibrosis

    Comparison of thalidomide and lenalidomide as therapy for myelofibrosis за авторством Elias Jabbour, Deborah A. Thomas, Hagop M. Kantarjian, Lingsha Zhou, Sherry Pierce, Jorge E. Cortés, Srđan Verstovšek

    Опубліковано 2011
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  8. 8
    Epigenetics of Acute Lymphocytic Leukemia

    Epigenetics of Acute Lymphocytic Leukemia за авторством Guillermo Garcia‐Manero, Hui Yang, Shao-Qing Kuang, Susan O’Brien, Deborah A. Thomas, Hagop M. Kantarjian

    Опубліковано 2008
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  9. 9
    DURAL PERMEABILITY TO NARCOTICS: IN VITRO DETERMINATION AND APPLICATION TO EXTRADURAL ADMINISTRATION

    DURAL PERMEABILITY TO NARCOTICS: IN VITRO DETERMINATION AND APPLICATION TO EXTRADURAL ADMINISTRATION за авторством Andrew Moore, Roy Bullingham, HJ McQuay, C. W. Hand, J.B. ASPEL, M. C. ALLEN, Deborah A. Thomas

    Опубліковано 1982
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  10. 10
    Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome‐related burkitt lymphoma/leukemia

    Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome‐relate... за авторством Jorge E. Cortés, Deborah A. Thomas, Adan Rios, Charles Koller, Susan O’Brien, Sima Jeha, Stefan Faderl, Hagop M. Kantarjian

    Опубліковано 2002
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  11. 11
    Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia

    Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute ly... за авторством Elias Jabbour, Susan O’Brien, Hagop M. Kantarjian, Guillermo Garcia‐Manero, Alessandra Ferrajoli, Farhad Ravandi, Maria E. Cabanillas, Deborah A. Thomas

    Опубліковано 2007
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  12. 12
    Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation

    Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation за авторством Fábio Pires de Souza Santos, Constantine S. Tam, Hagop M. Kantarjian, Jorge E. Cortés, Deborah A. Thomas, Raphael E. Pollock, Srđan Verstovšek

    Опубліковано 2013
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  13. 13
    Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post–Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

    Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post–Polycythemia Vera/Essential Thrombocythemia Myelofibrosis за авторством Constantine S. Tam, Hagop M. Kantarjian, Jorge E. Cortés, Alice Lynn, Sherry Pierce, Lingsha Zhou, Michael J. Keating, Deborah A. Thomas, Srđan Verstovšek

    Опубліковано 2009
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  14. 14
    A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas <scp>MD</scp> Anderson Cancer Center

    A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas <scp>MD</scp> Anderson Cancer Center за авторством Khanh Dang Vu, Nhiem Luong, Julie C. Hubbard, Ali Zalpour, Stefan Faderl, Deborah A. Thomas, Daisy Yang, Hagop M. Kantarjian, Michael H. Kroll

    Опубліковано 2014
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  15. 15
    Rituximab in relapsed or refractory hairy cell leukemia

    Rituximab in relapsed or refractory hairy cell leukemia за авторством Deborah A. Thomas, Susan O’Brien, Carlos Bueso-Ramos, Stefan Faderl, Michael J. Keating, Francis J. Giles, Jorge E. Cortés, Hagop M. Kantarjian

    Опубліковано 2003
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  16. 16
    Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy

    Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase recei... за авторством Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Dan Jones, Jianqin Shan, Gautam Borthakur, Deborah A. Thomas, Steven M. Kornblau, Susan O’Brien, Jorge E. Cortés

    Опубліковано 2009
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  17. 17
    Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside

    Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison w... за авторством Elihu H. Estey, Peter F. Thall, Francis J. Giles, Xuemei Wang, Jorge E. Cortés, Miloslav Beran, Sherry Pierce, Deborah A. Thomas, Hagop M. Kantarjian

    Опубліковано 2002
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  18. 18
    A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

    A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk m... за авторством Stefan Faderl, Farhad Ravandi, Xuelin Huang, Guillermo Garcia‐Manero, Alessandra Ferrajoli, Zeev Estrov, Gautam Borthakur, Srđan Verstovšek, Deborah A. Thomas, Monica Kwari, Hagop M. Kantarjian

    Опубліковано 2008
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  19. 19
    Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration

    Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration за авторством Hagop M. Kantarjian, Deborah A. Thomas, Farhad Ravandi, Stefan Faderl, Elias Jabbour, Guillermo Garcia‐Manero, Sherry Pierce, Jianquin Shan, Jorge E. Cortés, Susan O’Brien

    Опубліковано 2010
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  20. 20
    Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab – incidence and predictors

    Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab – incidence and predictors за авторством Gautam Borthakur, Susan O’Brien, William G. Wierda, Deborah A. Thomas, Jorge E. Cortés, Francis J. Giles, Hagop M. Kantarjian, Susan Lerner, Michael J. Keating

    Опубліковано 2007
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:

Інструменти для пошуку: